Briefing

Industry news

Industry briefing

Covid-19 briefing

NEWS

FDA expands EUA of Pfizer-BioNTech’s Covid-19 booster shot to adolescents

BRIEFING

Merck reports $952m in sales for molnupiravir

Merck expects to sell molnupiravir treatment courses worth $5-6bn this year

covid-19

Global economic growth is expected to slow down in 2022

Global growth is expected to be moderate at 4.4% compared to 5.9% in 2021 as per the IMF

Industry news

Industry briefing

Covid-19 briefing

02/16/2022 09:00:30
  • Home | Cutting the carbon footprint of pharma’s supply chain
  • In this issue
  • Contents
  • CSafe Global
  • Mimotopes Company Insight
  • Mimotopes
  • Briefing
  • Industry news
  • The pharma industry briefing
  • Covid-19 executive briefing by GlobalData
  • HOF Sonderanlagenbau
  • Comment
  • Is price control by stealth the future for the United States?
  • FDA approves Janus kinase inhibitors Rinvoq and Cibinqo despite safety concerns
  • Psychedelics: the next trip for CMOs
  • Over $1bn raised in venture capital funding for gene editing in 2021
  • Skyepharma
  • In Depth
  • How AI could unlock the medical potential of psychedelics
  • Covid-19 vaccine mixing: could heterologous boosters improve immunity?
  • Uneven supply patterns hinder US rollout of Covid-19 antivirals
  • Cutting the carbon footprint of pharma’s supply chain
  • Molnupiravir supplies dominate in times of Paxlovid scarcity
  • Wek-tec
  • In Data
  • Revealed: pharma leaders in precision, personalised medicine
  • Asia-Pacific is seeing a hiring boom in pharmaceutical cybersecurity roles
  • Venture financing deals in pharma rise in H2 2021
  • Global markets and indices
  • Macro-economic indicators
  • Macro-economic indicators (page 2)
  • Controlant Company Insight
  • Controlant
  • Event: Clinical Trial Supply New England 2022
  • Events
  • Next issue